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Abstract
Hemangiomas of Infancy: Mesenchymal Stem Cell Tumors of Perivascular Origin
Christopher Spock
Introduction: Hemangiomas of infancy (HOI) are the most common benign tumor of childhood.
Initially thought to be composed entirely of endothelial cells, it has recently been shown that
mesenchymal stem cells reside within these tumors. We propose that hemangiomas represent
mesenchymal stem cell tumors of pericyte origin, as demonstrated by expression of pericytic
markers (NG2, PDGFR-!, and DLK), neural crest origin (expression of nestin and sox10),
expression of factors that play a role in the maintenance of stem cell pluripotency (Oct4, Sox2,
Nanog, C-myc, and piRNAs), and a microRNA expression profile suggestive of mesenchymal
stem cells.
Methods: Quantitative RT-PCR was performed on 19 hemangioma specimens (4 proliferating,
10 plateau, 5 involuting) analyzing transcription factors (Oct4, Sox2, C-myc, and Nanog) known
to regulate stem cell pluripotency. Transcription factors RB, IGF2, CTCF, BORIS, DLK, and
CDX-2 were also examined. PiRNA analysis was performed on 7 hemangioma specimens to
investigate the role of these small RNA transcripts that interact with Piwi proteins expressed in
the germline and stem cells. MicroRNA microarray analysis was performed on 9 hemangioma
specimens. MicroRNA pathway analysis was performed using Ingenuity Pathway Analysis
software and MetaCore Software. Freshly resected hemangioma specimens were cultured in
embryonic stem cell media with and without recombinant human basic fibroblast growth factor
(rhbFGF), recombinant human transforming growth factor ! (rhTGF-!), and 17-! estradiol.
Results: All hemangiomas expressed factors RB, Oct-4, Sox-2, Nanog, C-myc, DLK, IGF-2, and
CTCF at higher levels than endothelial cell controls. DLK, a gene that functions as a negative
regulator of adipocyte differentiation, is increased in hemangiomas more than 105 orders of
magnitude compared to control endothelial cells. MiRNA-195, which is known to target DLK, is
also upregulated in hemangiomas. PiRNA analysis revealed that hemangiomas do not contain
piRNA transcripts. A microRNA microarray analysis using adult and neonatal dermal endothelial
cells as controls indicated that microRNAs associated with mesenchymal stem cells (miR-143,
miR320a, miR320c, let-7c) were expressed in 9 samples studied. Hemangioma growth in culture
was not observed in embryonic stem cell media with or without supplementation with bFGF and
TGF-!. Growth was observed in standard culture media with 17-! estradiol supplementation.
Conclusion: Hemangioma specimens in all stages of growth express transcription factors and
genes known to play a role in the maintenance of stem cell pluripotency at a level greater than
control endothelial cells. Specifically, transcription factors Oct-4, Sox-2, Nanog, and C-myc are
increased. Furthermore miR-143, miR320a, miR320c, and let-7c (all microRNAs identified in
mesenchymal stem cells) are upregulated in hemangioma tissue in all stages of growth. DLK, a
gene that functions as a negative regulator of adipocyte differentiation, is increased in
hemangiomas compared to controls. The downregulation of this gene may lead to transformation
of mesenchymal stem cells into adipose tissue. Future experiments are necessary to confirm this
role.
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Statement of Purpose:
Infantile hemangiomas possess interesting and complex characteristics that are
relevant to the fields of vascular biology, stem cell biology, oncology, immunology, and
dermatology among others. While a great deal is known about the clinical presentation
and natural history of these lesions, the exact cell of origin and the mechanisms of
pathogenesis of these lesions are not well understood.
Initial theories hypothesized that hemangiomas were of placental origin. As
important differences between hemangiomas and placental tissue were uncovered, the
search for the cell of origin turned to endothelial cells. Increased endothelial progenitor
cells are seen in these lesions, and other studies suggest that hemangiomas represent
clonal expansions of endothelial cells. The composition of hemangiomas is not limited to
endothelial cells; rather, mesenchymal stem cells play an important role in these lesions
and may contribute to the fibro-fatty residuum left behind when these lesions involute.
The nature of the mesenchymal stem cells in hemangiomas is not well
understood, and neither is the relationship between mesenchymal stem cells and
endothelial cells. Recent studies have shown that mesenchymal stem cells arise from the
perivasculature, specifically from pericytes, and can differentiate into a variety of tissues
including adipose. The working hypothesis of this research is that hemangiomas represent
aberrantly differentiated mesenchymal stem cells of a perivascular location and pericyte
lineage (CD146+, NG2+, PDGFB+, and DLK) that lead to a proliferation of endothelial
cells due to local hypoxia and paracrine effects of secreted growth factors.
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In order to investigate this hypothesis and classify the nature of the mesenchymal
stem cells in hemangiomas quantitative RT-PCR was performed on hemangioma
specimens analyzing various transcription factors (Oct4, Sox2, C-myc, and Nanog)
known to regulate stem cell pluripotency. Additional genes and transcription factors
known to play a role in hemangioma growth (IGF2, CTCF, BORIS, H19) were studied as
well, to see if there was a difference between hemangiomas in various stages of growth
compared to endothelial cell controls. Additional analysis of hemangioma specimens was
done using a microRNA microarray. MicroRNAs are small RNAs that have emerged as
potent regulators of gene expression. Analysis of microRNAs has been used to classify
various cancers and to elucidate molecular pathways involved in the pathogenesis of such
lesions. We performed a microRNA microarray assay to classify the expression profile of
hemangiomas and to identify new pathways that could be involved in the pathogenesis
and life cycle of hemangiomas.
A related set of small RNAs that play an important role in stem cell pluripotency,
known as piRNAs (named because of their interaction with Piwi-proteins) were analyzed.
We searched for the presence of piRNAs in hemangiomas because piRNAs are associated
with maintenance of stem cell pluripotency.
Finally, an attempt was made to develop a new culture-based hemangioma model
using stem cell media and specific stem cell growth factors. A better understanding of
how the genetics of hemangiomas affects the clinical course of disease will help
physicians predict clinical outcomes and tailor therapies to their individual patients.
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Introduction:
Classification
Hemangiomas of infancy (HOI) are the most common benign tumor in children.
Historically, the nomenclature of hemangiomas has been confusing, but the classification
system, described by Mulliken and Glowacki and refined by the International Society for
the Study of Vascular Anomalies, provides the best framework for understanding
hemangiomas and other vascular anomalies in infants and children.1,2 Within this
framework, vascular anomalies are classified as either hemangiomas or vascular
malformations on the basis of cellular features in relation to their clinical appearance and
natural history.
It is currently believed that hemangiomas are vascular tumors composed of
hyperplastic vascular endothelial cells that have the capacity to proliferate excessively.
Regarded as neoplasms, they grow by rapid endothelial proliferation and are
characterized by hypercellularity.3 Hemangiomas are often absent or small at birth, but
then grow rapidly in early infancy during what is known as a proliferative phase. Then,
for an unknown reason, these tumors undergo regression and involution as part of their
normal life cycle. As a hemangioma involutes, fibro-fatty tissue is deposited in its place,4
but the origin of this tissue has yet to be determined.
Immunohistochemical markers are used to identify hemangiomas, and GLUT1, a
glucose transporter normally expressed in the microvascular endothelium of blood-tissue
barriers such as brain, retina, placenta, and endoneurium, but not normal skin, is a
specific marker for hemangiomas of infancy in all phases of development. GLUT-1 is
strongly expressed in the entire endothelial lining of hemangioma vessels, but it is absent
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in other vascular lesions, such as malformations, pyogenic granulomas, granulation
tissue, as well as rapidly involuting and non-involuting congenital hemangiomas.5 It is
therefore used to distinguish hemangiomas from other lesions.
Hemangiomas are sub-classified into hemangiomas of infancy (HOI), rapidly
involuting congenital hemangiomas (RICH), and non-involuting congenital hemangiomas
(NICH). Both RICH and NICH present fully-developed at birth and remain static or
rapidly involute. They are histologically and immunohistochemically distinct from HOI,
most notably because NICH and RICH do not test positive for GLUT-1. The experiments
described in this thesis relate specifically to hemangiomas of infancy. Therefore, the term
hemangioma will be used to refer only to HOI and not RICH or NICH for purposes of
clarity throughout the text.
In contrast to hemangiomas, vascular malformations result from structural
abnormalities of endothelial cells that are usually present at birth, are relatively mature at
presentation, and do not exhibit a tendency towards hyperplasia with rapid proliferation.
Vascular malformations display a normal pattern of growth, enlarge as the child grows,
and do not spontaneously resolve.

Epidemiology
Hemangiomas of infancy are the most common tumor of childhood and affect
between 10% and 12% of all Caucasian children.6 For reasons not well understood
hemangiomas are more common in females compared with males at rates of 3:1 to 5:1.7
Hemangiomas also show a predilection for the head and neck anatomic region, and in one
study of 178 hemangiomas, approximately 60% were located on the head and neck.8
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Hemangiomas are more common in premature infants, and increased prevalence of
hemangiomas correlates with both earlier gestational age and decreasing birth weight. 9, 10
In addition, chorionic villus sampling (CVS) at 9 to 12 weeks of gestation has been
associated with an increased incidence of hemangiomas in infants. In one study the
incidence of hemangiomas was 21% with chorionic villus sampling versus 7% with
amniocentesis.11 It should be noted, however, that a more recent study found no
association with CVS.12 The underlying reasons for these clinical characteristics:
preferential location on the head and neck, increased prevalence in premature infants, and
possible association with CVS, could all be related to a hypoxic insult or stimulus as the
triggering factor for hemangioma development. The specifics of this hypothesis are
discussed in greater detail in the section discussing the pathogenesis of these lesions.

Clinical Presentation
On initial presentation hemangiomas typically appear as an erythematous pink or
red macule, a blanched spot, or a telangiectasia surrounded by a pink halo.13 Several
studies have documented that approximately 40% of hemangiomas are present at birth as
a small red mark.2,8 The cellular composition of this early macular stage is not well
understood. In future studies it would be helpful to biopsy these lesions in the earliest
proliferative stages to identify the cell sub-types present, and for reasons explained later,
to see if genes that activate in response to hypoxia are upregulated.
The natural history of these hemangiomas of infancy is well described and
involves a proliferative phase early in infancy followed by an involutional phase of
variable length occurring after the first year of life.8 Hemangiomas often reach their
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maximum size by 9 to 12 months or earlier, although there is a subset that continues to
proliferate for up to 18 to 24 months.4
Involution begins as early as a few months after lesion appearance, with the usual
onset at 12 to 18 months. The process usually begins centrally in the lesion and spreads
peripherally. Complete involution occurs at an estimated rate of 10% per year, and a
convenient way to remember the rate of involution is to consider that 50% have involuted
by 5 years of age, 70% by age 7, and 90% by age 9.4
During involution there is a decreased amount of endothelial cell label uptake and
decreased number of mast cells, with the tissue being replaced by fibro-fatty stroma
during this phase.3 Detailed knowledge of the clinical behavior of these lesions is
important because it provides clues to the underlying genetic mechanisms governing
hemangioma origin and pathogenesis, two major questions that remain to be answered
regarding hemangiomas. Despite our clinical knowledge one of the most important areas
of research is determining the cell of origin of hemangiomas.

Hemangioma Origins – Placental Connection
Multiple lines of evidence point to similarities between placental tissue and
hemangiomas. The increased incidence of hemangiomas in children whose mothers had
underwent chorionic villus sampling led initial support to this hypothesis.11 It was
reasoned that the trauma of CVS increased the number of placental cells released into the
circulation and thus increased the likelihood that these cells embolized to fetal vascular
sites.
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Further support of the hemangioma-placenta connection comes from the fact that
hemangioma tissue bears striking resemblance to placental tissue. Placental vasculature
and hemangioma tissue share expression of several surface markers. It has been
demonstrated that both tissues express merosin, Lewis Y, Fc"RII (CD32), and glucose
transporter 1 (GLUT-1, also expressed on endothelium of blood-brain barrier and red
blood cells).14,15 Another group performed microarray analyses on placenta, hemangioma,
and eight other normal and diseased tissues and determined that the transcriptome
similarity between placenta and hemangioma exceeded that of any other tissue and
mirrored that seen between normal lung parenchyma and pulmonary tumors.16
Interestingly, the lifecycle of the placenta resembles that of hemangiomas. As the
placenta develops, angiogenesis occurs at an extraordinary rate, and it is controlled by
inhibitory factors that prevent inappropriate blood vessel growth into normal maternal
and fetal tissue. In order to prevent uncontrolled angiogenesis the placenta produces a
soluble form of the VEGF transmembrane receptor, sFlt-1, that is found in both maternal
serum and amniotic fluid and serves to inhibit angiogenesis by sequestering circulating
VEGF and placental growth factor.

17,18

With the passage of the placenta, the source of

sFlt-1 is removed allowing unopposed proliferation of cells responsive to angiogenic
growth factors. This sequence not only mirrors the natural history of hemangiomas, but it
coincides chronologically with the appearance of infantile hemangiomas in the postnatal
period.
Despite these similarities between placenta and hemangioma, the embolization
theory is an oversimplification of the origin of hemangiomas, and there is strong evidence
contradicting it. A study by Bree et al. demonstrated that the immunohistochemical
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profiles of hemangiomas and placental tissue are not exactly identical. Infantile
hemangiomas failed to stain for certain trophoblastic markers such as human placental
lactogen, placental alkaline phosphatase, and cytokeratins 7, 8, and 11.19 Another study
investigated maternal-fetal chimerism and demonstrated that hemangiomas are
exclusively derived from the child, with no evidence of maternal origin20 as would be
expected if hemangiomas were in fact embolized placenta. The similarities between
placental tissue and hemangiomas, however, have generated new ideas regarding the
origins of these tumors.

Hemangioma Origins – Endothelial Progenitor Cells
Recent evidence suggests that several different types of progenitor cells may play
a role in hemangioma progression. The identity of endothelial progenitor cells is
controversial, however, most agree that a single marker cannot identify these cells. The
likely identity of endothelial progenitor cells comes from studies21 that have shown that
cells expressing both CD34 and AC133 (CD133) can differentiate into endothelial cells
in vitro." Normal bone marrow and peripheral blood contain such progenitor cells that
can then differentiate into endothelial cells22, 23 through the process of vasculogenesis.
Vasculogenesis occurs through a sequence of events, typically set in motion by a
hypoxic insult to peripheral tissues which then leads to recruitment of endothelial
progenitor cells from the bone marrow and subsequent vascular assembly. These
endothelial progenitor cells must undergo mobilization from the bone marrow stroma,
followed by selective homing, extravasation, differentiation, and tubule formation,

"

For a complete listing of the cellular markers discussed in this text see Image 2.
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ultimately leading to new blood vessel formation.24 Vasculogenesis is differentiated from
angiogenesis in which the growth of new blood vessels occurs via extension and
remodeling from existing vasculature.25
The endothelial progenitor cells responsible for vasculogenesis may play an
important role in hemangiomas as peripheral blood collected from patients with
hemangiomas demonstrated a 15-fold increase in circulating endothelial progenitor cells.
Those same progenitor cells also co-expressed the known hemangioma markers GLUT1,
CD32, and merosin.26 Another group was able to demonstrate the presence of these
endothelial progenitor cells in actual hemangioma specimens.27 Eleven of twelve
proliferating hemangiomas in this group’s cohort demonstrated CD133+/CD34+
endothelial progenitor cells. However, no such cells were identified in involuting
hemangiomas. Of note, one of the specimens in this group did not contain endothelial
progenitor cells, which suggests that perhaps these cells do not play a role in all
hemangiomas.
Given this data, it is unclear if increased numbers of endothelial progenitor cells
are the cause or effect of hemangioma formation. One postulation is that vascular
progenitors are recruited to the hypoxic environment of hemangiomas through
stabilization of the global regulatory protein HIF-1# and increased expression of the
downstream effectors SDF-1# and VEGF. In addition to attracting and concentrating
endothelial progenitor cells within the tumor, these chemokines mediate the assembly of
progenitor cells into new vascular structures.28
The origin of the endothelial cells in hemangiomas is an important area of
investigation. Several studies have tried to determine if hemangiomas are clonal lesions.
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These studies examined hemangioma clonality using X-linked human androgen receptor
gene assay (HUMARA) analysis. One study analyzed cells grown in culture from seven
patients, and all showed a skewing toward a single allele.29 A subsequent study analyzed
intact tissue without selection of cells and found some degree of allelic loss in 12 of 14
samples.30 These two independent investigations suggest that hemangiomas arise as a
consequence of clonal expansion from a single cell; however, it is possible that sampling
constraints biased these results. It is usually only possible or practical to sample a portion
of a hemangioma lesion and therefore conceivable that clonality accounts for only
portions of the lesion. This argument against clonality seems even more plausible when
one considers segmental hemangiomas, which are large and plaque-like. If these lesions
were clonal then large numbers of cells derived from a single precursor would need to
spread over a large anatomic area and expand simultaneously.
Although the clonal nature of hemangiomas is debatable it is well established that
hemangiomas are not composed entirely of one cell type and while endothelial progenitor
cells may play a role in these lesions, other cells should not be excluded from this
discussion. Mesenchymal stem cells are another important population of cells isolated
from hemangiomas, and these cells may be responsible for the unique life cycle of the
tumor.

Hemangioma Origins – Mesenchymal Stem Cells
During involution the tissue at the site of the hemangioma develops into fibroadipose tissue. Little is known about the process by which this occurs, although
mesenchymal stem cells may play a role. A group recently identified mesenchymal stem
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cells within hemangioma tissue that are distinct from endothelial progenitor cells.31 This
suggests that there are at least two distinct cell populations within hemangiomas.
Mesenchymal stem cells are defined by their self-renewal capability and potential
for multi-lineage differentiation into adipocytes, osteoblasts, chondrocytes, myocytes,
neuronal cells, and hepatocytes.32 Mesenchymal stem cells are observed in hemangiomas
more frequently than in normal skin, and their numbers are highest during the
proliferative phase.31 Furthermore, these cells exhibit a random pattern of X-chromosome
inactivation indicating that they are not clonally derived.31 The cells recovered from
hemangiomas are found to have many of the characteristics of mesenchymal stem cells
from other tissues, and it has been hypothesized that these cells may contribute to the
generation of adipocytes during hemangioma involution.
Hemangioma derived mesenchymal stem cells expressed the cell surface markers
SH2 (CD105), SH3, SH4, CD90, CD29, smooth muscle actin, and CD133 but not the
hematopoietic markers CD45 and CD14 or the hematopoietic/endothelial markers CD34,
CD31.31 This is evidence to the fact that hemangioma derived mesenchymal stem cells
represent a distinct population of cells from the endothelial progenitor cells
(CD34+/AC133+) in hemangiomas of infancy. It should be mentioned that these cells
were CD34- but flow cytometry was performed on them after they had been cultured, and
recent evidence indicates that mesenchymal stem cells may lose CD34 positivity in
culture.33
Additional evidence linking stem cells to hemangiomas was demonstrated by
Boscolo et al. in an experiment that isolated stem cells from hemangioma specimens and
then injected them subcutaneously into the back of immunodeficient mice. These stem
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cells were able to differentiate and organize into functional vessels 7-14 days after
implantation. Furthermore these vessels were CD31+/GLUT1+, and two months after
implantation the number of blood vessels diminished and human adipocytes became
evident.34 Unfortunately, the specific markers used by this group to isolate stem cells is
not well-described in their abstract and it is unclear what specific population of cells this
group was isolating prior to implantation.
Until recently the origin of mesenchymal stem cells was not known. But,
groundbreaking work has demonstrated that mesenchymal stem cells arise from the
perivasculature and these precursor cells have the potential to develop into adipose,
muscle, bone, and cartilage. Using lineage tracing in mice a group demonstrated that the
precursor cells that give rise to adipocytes reside within the walls of the blood vessels
that supply adipose tissue35 (See Image 1). Pericytes, the smooth muscle-like cells that
cover the endothelial cells of blood vessels, give rise to adipocytes. These specialized
cells express the proteins peroxisome proliferator-activated receptor $ (PPAR-$), stem
cell antigen 1 (sca1), and CD34. This cell population also expresses smooth muscle actin
(SMA), platelet-derived growth factor receptor-! (PDGFR-!), and neural/glial cell 2
(NG2), which are all markers of pericytes, but not perilipin, a marker of mature
adipocytes. Previously the only known marker of pre-adipocytes was Pref-1 (also known
as DLK-1), a cell surface protein in the epidermal growth factor family.36 DLK-1
functions as a negative regulator of adipocyte differentiation, and we hypothesize that
this protein may play a critical role in the conversion of hemangiomas into adipose tissue.
The identification of these adipocyte precursor cells has important implications
regarding hemangiomas. Although Tang et al.35 find the PPAR-$ expressing cells only in
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blood vessels that supply adipose tissue, pericytes isolated from other locations have
adipogenic, myogenic, osteogenic, and chondrogenic potential.37 Most pericytes,
adipocytes, myoblasts, and osteoblasts are thought to be of mesodermal origin, and in all
four cases similar cell types in the head and neck appear to derive from neural crest.38, 39
It is therefore possible that the pericyte is the cell of origin of the hemangioma. We
hypothesize that hemangiomas of the head and neck are derived from neural crest
pericytes (which may be uniquely sensitive to hypoxia) and that hemangiomas in other
anatomic locations arise from mesoderm derived pericytes.

Hemangioma Origins – Pericytes
Pericytes closely encircle endothelial cells in capillaries and microvessels.40
Pericytes also inhibit the division of endothelial cells via TGF-! activation.41 If one
considers the role of pericytes in hemangiomas this could be a potential explanation for
why hemangiomas do not become invasive secondary to uncontrolled angiogenesis.
Pericytes can be isolated in multiple human organs including skeletal muscle,
pancreas, adipose tissue, and placenta using CD146+, NG2, and PDGF-R! expression in
the absence of hematopoietic, endothelial, and myogenic markers.37 Neural/glial cell 2
(NG2), also known as chondroitin sulfate proteoglycan, is a proteoglycan associated with
pericytes during vascular morphogenesis.42 CD146 (aka S-endo1, Mel-CAM, Muc18, or
gicerin) is an endothelial cell antigen also expressed at the surface of pericytes.43 In
addition to NG2 and CD146, all perivascular cells express PDGF-R! but do not express
endothelial cell markers such as CD144 (VE-cadherin), von Willebrand factor (vWF),
CD34, or CD31.37 The expression of PDGF-R! is of particular interest because cases of
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familial hemangiomas have mapped to chromosome 5q31-33 which harbors the genes for
FGF receptor 4, and PDGF-R!.44
The connection between mesenchymal stem cells and perivascular cells is
strengthened by the work of Crisan et al. This group demonstrated that mesenchymal
stem cells are derived from perivascular cells (CD146+/NG2+/PDGF-R!+/CD34/CD144-/CD31-/vWF-) on the basis that these cultured perivascular cells express all
recognized markers of mesenchymal stem cells including CD10, CD13, CD44, CD73,
CD90, and CD105, as well as CD108, CD109 (platelet activation factor), CD140b
(PDGFR-!), CD164, CD166, CD318, CD340 (HER-2), CD349 (frizzled-9), SSEA-4, and
HLA-CL.37 Interestingly another group found that the mesenchymal stem cells isolated
from adipose tissue express CD34 (but remain CD31-/CD45-) indicating that
mesenchymal stem cell expression of CD34 may be rapidly down-regulated in culture.33
Additional studies have shown that these multipotent mesenchymal stem cells of
perivascular origin serve both structural and functional roles in interactions with
endothelial cells.33 Mesenchymal stem cells and endothelial cells in co-culture exhibit
preferential heterotypic assembly into vascular networks in vitro, which demonstrate a
stability advantage in comparison with networks of endothelial cells alone. It is believed
that paracrine interactions between these mesenchymal stem cells and endothelial cells,
due to secreted proteins such as VEGF and bFGF, mediate this stability advantage. The
role of secreted factors VEGF and bFGF is of particular importance because it has been
hypothesized that the use of !-blockers in the treatment of hemangiomas of infancy
works because of the downregulation of these specific factors.45 Applying this knowledge
to hemangiomas one can hypothesize that hemangiomas represent mesenchymal stem cell
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tumors of perivascular origin that recruit and/or direct the assembly of endothelial cells in
response to a hypoxic insult.

Mechanisms Controlling Hemangioma Growth – Role of IGF-2
In addition to determining the cell of origin of hemangiomas much work has been
done to elucidate the genetic mechanisms that control the growth of these lesions. In fact,
exploration into the mechanisms controlling hemangioma growth may provide further
insight into the cell of origin of these fascinating lesions.
Large scale gene expression analysis of proliferating versus involuting
hemangiomas has shown that insulin-like growth factor 2 (IGF-2) is highly expressed
during the proliferative phase and substantially decreased during the involuting phase of
hemangioma growth.46 Ritter et al. also showed that IGF-2 promotes sprouting from
intact hemangioma tissue using a human hemangioma explant model.
Human insulin-like growth factor (IGF-2) is an important mitogen which plays a
role in normal fetal and postnatal growth, and also in tumorigenesis.47 Regulation of the
human IGF2 gene is very complex, both at the transcriptional and post-transcriptional
level. IGF2 lies 110-200 kb centromeric to H1948 a gene whose transcript is not
translated,49,50 but whose molecular evolution suggests a functional role for its mRNA
perhaps in tumor suppression. IGF2 and H19 are reciprocally imprinted, such that H19 is
transcribed exclusively from the maternal allele, and IGF2 is transcribed from the
paternal allele. H19 participates in the repression of IGF2, at least in part through effects
on IGF2 transcription, an effect that may contribute to its action as a tumor suppressor.51
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A differentially methylated region (DMR) with paternally derived methylation is
located 2kb upstream of H19. This region acts as an insulator when unmethylated and
binding sites for CTCF (CCCTC-binding factor) are exposed. CTCF is a ubiquitous 11zinc finger protein with highly versatile functions such as transcriptional silencing or
activating depending on the context. CTCF is also known as the Regulator of Imprinted
Sites (RIS) because of its ability to partition DNA into active and inactive regions by
insulating genes from proximate enhancers.52,53 CTCF possesses numerous recognized
functions ranging from X chromosome inactivation to genome wide regulation, and its
function is critical for normal cellular processes.54-57 Numerous studies have shown
CTCF binding to DNA to be methylation sensitive.58-61
Previous work by Narayan’s lab investigated the IGF-2/H19 locus, specifically
looking at methylation changes in the promoter region. Analysis of methylation changes
at this locus and sequencing has identified a C to T polymorphism62, 63 in this promoter
region where CTCF binds. Narayan’s group was the first to observe that hemangiomas
with this polymorphism had a faster time to regression.64 This is the first consistent
genetic phenomenon associated with non-familial infantile hemangiomas.
Furthermore, studies in Narayan’s lab identified a pathologic protein, BORIS
(Brother of the Regulator of Imprinted Sites), which is normally only expressed in the
testis.65 While CTCF over-expression blocks cell proliferation, expression of BORIS in
normally BORIS-negative cells promotes cell growth that can lead to transformation.65
As previously mentioned, IGF-2 is epigenetically regulated so that only the
paternal allele is expressed in most tissues prenatally and in some tissues during postnatal
life, a phenomenon referred to as genomic imprinting. Preferential loss of maternal alleles
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(loss of heterozygosity) and relaxation of parental imprinting (loss of imprinting) of IGF2
occurs frequently in certain pediatric tumors such as Wilms’ tumors, adrenocortical
carcinomas, hepatoblastomas and rhabdomyosarcomas, and in malignant adulthood
tumors (including uterine, lung, and testicular tumors) suggesting that abnormal
expression of IGF2 and/or of other 11p15.5 imprinted genes has a role in the
pathogenesis of these diseases. However, a study by Yu et al. showed that loss of
imprinting of IGF2 is not involved in the increased expression of IGF2 in infantile
hemangioma.66
Given that a normal pattern of IGF-2 imprinting is found in hemangiomas,66 it is
possible that an abnormal response to hypoxia could explain the high levels of IGF-2 in
these lesions. Hypoxia, or low levels of oxygen, is sensed by cells, which then respond by
modifying gene expression. Hypoxia-inducible factor 1# (HIF-1#) is a major
transcription factor that serves as a major regulator of the cellular response to hypoxia.
HIF-1# is involved in several cellular processes including regulation of differentiation
and myeloid cell function,67 regulation of genes involved in angiogenesis, erythropoiesis,
energy metabolism, inflammation, and cell survival.68 GLUT-1 and IGF-2 expression are
both under control of HIF-1# and are induced by hypoxia.69, 70
Hypoxia is a potent stimulus for neovascularization and its effects are largely
mediated by the regulatory transcription factor hypoxia inducible factor-1# (HIF-1#).
Increased HIF-1# activity in turn promotes expression of downstream hypoxia
responsive genes such as vascular endothelial growth factor (VEGF) and stromal derived
factor-1# (SCF-1#).71,72 Both VEGF and SDF-1# are critical for the recruitment,
trafficking, and incorporation of endothelial progenitor cells into new blood vessels.72
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It has been demonstrated that proliferating hemangiomas exhibit significant
hypoxia, leading to HIF-1# upregulation/stabilization and subsequent expression of
downstream targets.73 It was also shown that in human tissues there was increased HIF1# expression in proliferating hemangioma samples with corresponding increases in
VEGF and SDF-1#. Involuting samples did not demonstrate any upregulation of HIF-1#.
The idea of a hypoxic insult leading to new vessel growth is an intriguing
hypothesis because it has been shown that the location of hemangiomas is not random 74
and may be related to areas of hypoxia. This study found that facial hemangiomas
occurred in regions close in proximity to lines of fusion between mesenchymal growth
centers or between mesenchymal growth centers and facial ectoderm. Interestingly, the
mesenchyma of the head is derived from neural crest cells.
Neural crest-derived mesenchyma might possess unique properties that make it a
particularly receptive field for externally derived vascular precursors. For example, it has
been shown in chick-quail chimeras that this neurally-derived mesenchyma, unlike
mesoderm-derived mesenchyma, has no endogenous angioblasts and must rely on
migrating angioblasts and vascular sprouts for vascularization.75 Given the increased
need for in-migration of angioblasts one can hypothesize that regions of the head may be
subjected to areas of hypoxia due to lack of blood supply, which could then lead to
upregulation of HIF-1#.

Mechanisms Controlling Hemangioma Growth - microRNA Regulation
The underlying mechanisms that control expression of the IGF-2/H19 locus are
still being uncovered. One potential mechanism of regulation of this locus could involve
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small non-coding RNAs, specifically microRNAs, which have emerged as potent
regulators of gene expression at both the transcriptional and post-transcriptional levels.
MicroRNAs (miRNAs), a non-coding RNA family, are 19 to 25 nucleotide (nt)
transcripts that are cleaved from 70 to 100-nt hairpin-shaped precursors. The sequences
of many miRNAs are conserved between distantly related organisms, suggesting that
these molecules participate in essential processes. Although the precise biological
functions of miRNAs are not yet fully understood, they have diverse expression patterns
and may regulate various developmental and physiological processes. Moreover,
dysregulation of miRNA expression might contribute to human disease.
The first identified miRNAs, the products of the C. elegans genes lin-4 and let-7,
have important roles in controlling developmental timing and probably act by regulating
mRNA translation. When lin-4 or let-7 is inactivated, specific epithelial cells undergo
additional cell divisions instead of their normal differentiation. Because abnormal cell
proliferation is a hallmark of human cancers, it seems possible that miRNA expression
patterns might denote the malignant state. Indeed, altered expression of a few miRNAs
has been found in some tumor types.76 Several papers have recently been published that
explore analysis of miRNAs as a way of classifying tumors.76-78 For example, Murakami
et al.78 looked at miRNA expression to classify the degree of differentiation of
hepatocellular carcinoma.
Previous work by Narayan’s group identified miRNAs that would interact with
transcription factors CTCF and BORIS. This work began as a search to identify an
additional epigenetic control mechanism at the IGF-2/H19 gene locus. Through multiple
prediction algorithms, a set of two related miRNAs (mir23a and mir23b) that potentially
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target both CTCF and BORIS were identified. The implication was that miRNA could
potentially affect imprinting. By correlating mir-23a and mir-23b to CTCF and BORIS
levels in the hemangioma samples tested, mir-23a correlated with CTCF and BORIS
downregulation equally well, while mir-23b correlated with CTCF downregulation. In
addition, the difference between mir-23a and mir-23b strongly correlated with the
difference between CTCF and BORIS. Data indicated that mir-23b could be a potential
anti-target of BORIS relative to CTCF; thus, increased mir-23b compared to mir-23a
expression would effectively lead to increased levels of BORIS over CTCF.
MicroRNAs, however, serve a diverse set of functions and analysis of miRNA
expression profiles of hemangiomas could give important insight into the molecular
pathways involved in the pathogenesis of these lesions. Furthermore, analysis of miRNA
expression could also give insight into the cell of origin of hemangiomas. Several studies
have identified populations of miRNAs that are associated with specific stem cell types.
MicroRNAs mediate regulation of stem cell division,79 as well as differentiation in
adipocyte,80 cardiac,81 neural,82 and hematopoietic lineages.83 By comparing the miRNA
expression profile of hemangiomas to normal endothelial cell controls we hope to
describe the specific pathways involved in the pathogenesis of these lesions.

Mechanisms Controlling Hemangioma Growth – piRNA Regulation
Assuming that hemangiomas of infancy represent tumors of stem cell origin it
will be important to identify other potential regulators of the growth and clinical behavior
of these lesions. Previous work by Narayan’s lab identified that hemangiomas produce
BORIS, a pathologic protein that is normally only expressed in the testes. BORIS is a
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member of the cancer-testis (CT) gene family that comprises genes normally expressed
only in the testis, but abnormally activated in different malignancies. Its normal role in
the testis consists of resetting genome-wide DNA methylation during spermatogenesis.84
Hemangiomas, however, are the first benign tumor discovered to express this protein.
Given this localization of BORIS to the testis we hypothesized that other testisspecific regulatory proteins could be expressed in hemangiomas. Piwi proteins, a subclass
of the family of Argonaute proteins, are expressed in germline and stem cells and they are
associated with a unique set of small RNAs called piRNAs.
Recently discovered piRNAs (Piwi-interacting RNAs) represent an additional
class of small non-coding RNAs distinct from microRNAs. This class of small RNAs
differs from small interfering RNA (siRNAs) and microRNAs (miRNAs) in several
important ways.

85-88

First, piRNAs interact with the Piwi, but not the Argonaute (Ago)

subfamily of the Piwi-Ago family proteins. Second, piRNAs are 24 to 31 nucleotides
instead of ~21. Third, piRNAs consist of more than 50,000 different species in contrast to
hundreds of miRNAs. Fourth, these piRNAs are produced from long single-stranded
precursors in contrast to siRNAs and miRNAs that are derived from double-stranded and
short-hairpin RNA precursors, respectively.
Most piRNAs map to unique sites in the genome, including intergenic, intronic,
and exonic sequences. For this reason piRNAs may have diverse functions including
epigenetic programming, repressing transposition, and post-transcriptional regulation.
Each of these speculated roles is supported by the known function of the partner Piwi
proteins. For instance, Piwi is an epigenetic regulator.89 It co-localizes with Polycomb
group (PcG) proteins to cluster PcG response sequences in the genome.90 It is thus
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possible that Piwi-associated piRNAs may be involved in epigenetic regulation. In
addition, Piwi prevents retrotransposon transposition in the testicular germ line, which
suggests a second role of Piwi-associated piRNAs.91
The possible role of Piwi-associated piRNAs in the germline and in maintenance
of stem cell pluripotency is what led us to further investigate the role of these RNAs in
hemangiomas. We hypothesize that hemangiomas would express a unique pattern of
piRNAs, the classification of which would provide further insight into the origin and
pathogenesis of these lesions.

Growth of Hemangioma in Culture
One of the biggest limitations to hemangioma research has been the lack of a
viable animal model. Currently available experimental models of hemangiomas include
induction in mice via transgenic endothelial cells,92 mouse endothelial cells that have
been transformed by polyoma middle T oncogene,93,94 and endothelial cells obtained
from murine and human hemangiomas.95 However, tumors generated from these cell
lines have more malignant characteristics, are not obligately perinatal, and do not
spontaneously regress.
An ex vivo culture system has been developed that uses intact human hemangioma
tissue and permits biochemical manipulation.96 However, while this model does produce
microvascular outgrowths in culture, the hemangioma endothelial cells are not GLUT-1
positive.
Additional models which use purified cultures of hemangioma-derived cells have
been used to demonstrate the unusual behavior of hemangiomas in terms of growth and
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migration,29,97 but these models lack the environmental factors found in vivo as
potentially important growth factors, components of extracellular matrix, and direct
influence from surrounding cells are not present. Drawbacks of this model also include a
loss of cellular features of hemangioma endothelial cells and GLUT-1 expression.
It is clear that hemangiomas involve a population of both endothelial cells and
multi-potent mesenchymal stems cells of perivascular origin. It seems that the interaction
between these two cell populations leads to the growth of hemangiomas, and a successful
model of hemangiomas will need to incorporate this synergistic effect.
Also of relevance to the development of a hemangioma model is the growth
response of hemangiomas to estrogen. One group was able to demonstrate the response of
hemangioma vascular endothelial cells to estrogen in vitro.98 Elevated levels of 17-!
estradiol99 had previously been reported in children with hemangiomas. Xiao et al.
demonstrated that the combination of 17-! estradiol and endothelial cell growth
supplement in medium had a dramatic effect on proliferation of hemangioma endothelial
cells in culture. The GLUT-1 positivity of these cells, however, was not verified. We
hypothesize that if hemangiomas represent a population of mesenchymal stem cell
tumors that culture media for stem cells would lead to in vitro proliferation of these cells.
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Methods:
Specimen Collection
(Performed by the student)
All samples were collected in accordance with an approved HIC protocol
(#0507000430) as reviewed by the Yale University Medical School IRB. As these
samples were collected from children, fully informed parental, and childhood assent
when age appropriate, was obtained prior to surgery. Only the tissue remaining following
collection of the pathological specimen was used for this experiment. Specimens for
transcriptional analysis were separated into three categories: 1) proliferative, 2) quiescent,
and 3) involuting phases. These categories were determined on a clinical basis, as well as
by age. Proliferative hemangiomas: Less than 1.5 years of age with interval growth
between the last two clinic visits preceding surgery. Quiescent hemangiomas: Older than
1 year demonstrating no interval growth between the last two clinic visits preceding
surgery. Involuting hemangiomas: At least two years old with interval regression by
measurement between the last two clinic visits preceding surgery. Human dermal
microvascular endothelial cells (HDMEC), human umbilical vein endothelial cells
(HUVEC), human adult endothelial cells, and neonatal endothelial cells were used as
controls.

RNA preservation and extraction
(Performed by the student)
Immediately following tissue resection, 100-500mg of tissue was minced in 10ml
of Qiagen RNA Later solution with straight razors into pieces no larger than 1mm in any
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dimension. Samples were stored in 50mL Falcon tubes with an additional 10mL of RNA
Later solution. Samples were then stored at -20 degrees Celsius overnight and then frozen
at -80 degrees Celsius until RNA extraction could be completed. RNA was extracted by
first allowing the RNA Later solution to thaw. This was followed by straining of the
sample and immediate liquid nitrogen powder homogenization with a mortar and pestle.
All implements were baked at 200 degrees Celsius to eradicate RNAase enzymes.
Following homogenization, RNA was extracted using Invitrogen Trizol reagent
according to manufacturer’s specifications with the following exceptions. Once the initial
phase separation was accomplished with the addition of phenol/chloroform, the samples
were vigorously vortexed to shear genomic DNA. This helps ensure that the DNA will
migrate completely into the organic phase instead of remaining at the inter-phase, which
may contaminate the RNA sample. Following the phenol/chloroform extraction, the
supernatant (aqueous RNA phase) was subjected again to a 1/24 iso-amyl-alcoholchloroform extraction to minimize potential phenol contamination, which could inhibit
downstream enzymatic applications. After the isopropyl alcohol precipitation and ethanol
washing steps, the pellets were allowed to dry for 15 to 30 minutes and were resuspended in nuclease free water and stored at -80 degrees Celsius. To remove potential
genomic contamination, 10$g of total RNA from each sample was then treated with
DNase Qiagen mini-elute columns according to manufacturer’s specifications. RNA
integrity was then assessed using 1 $l of sample on the Agilent bioanalyzer 2100
(provided as a service of the Keck Center at Yale University). Band intensities of 18s and
28s RNA were quantitated and samples with an 18S/28S ratio of 1.8 or greater were
utilized for quantitative RT-PCR. Following quality control each sample was converted
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into cDNA using the ABI 4368813 cDNA archive kit. All samples were then stored at
-80 degrees Celsius.

5’ end-labeling of RNA for piRNA detection
(Performed by the student)
Dephosphorylation of RNA
Shrimp alkaline phosphatase (SAP) dephosphorylation reaction was first
performed on the RNA samples. The amount of sample needed for 2µg of RNA based on
concentration was calculated. Next the amount of H2O needed to bring the reaction
volume up to 16.5µL was calculated. A master reaction mix of 10X SAP buffer, RNase
Out, and SAP was made. A reaction mix of 3.5µL/tube was added for each sample
(leaving 16.5µL for RNA and H2O). Once the reaction mix, RNA, and H2O were added
to the tubes the reaction tubes were placed at 37˚C for 1 hour and then at 65˚C for 15
minutes in order to inactivate the SAP. The tubes were then stored at -80˚C.

5’ end-labeling of RNA
A master mix for the end labeling reaction was made from 30µL of 10x T4PNK
buffer, 5µL of RNase Out, 10µL of T4PNK (15U), and 55µL of H2O. Then 10µL of
master mix was added to each reaction tube from the dephosphorylation step bringing the
total volume of each reaction tube to 30µL. The reaction tubes were then incubated at
37˚C for 1 hour. Next 1.5µL of 0.5M EDTA was added to each reaction tube and the
tubes were incubated at 65˚C for 15 minutes. The unincorporated 32-P nucleotides were
removed by spinning the samples through Roche G25 mini quick oligo spin columns. The
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Roche oligo columns were prepared in the following fashion: First the columns were
allowed to warm to room temperature. The top cap was removed from each column and
then the bottom tip was snapped off. The columns were placed in Eppendorf tubes and
then spun at 1200x for 1 minute. The columns were then placed in clean, labeled
Eppendorf tubes and the labeled samples were pipetted directly onto the middle of the
matrix. The columns were then spun at 1200x for 4 minutes in order to collect the labeled
sample in the flow-through. The columns with the unincorporated nucleotides were then
discarded into a closed container in order to keep the ‘hot’ column matrix contained. The
labeled flow-through was then confirmed with a Geiger counter. To each sample tube
3µL of 6x load dye and formamide was added and the tubes were then stored at -20˚C.

Running Labeled RNA on denaturing poly-acrylamide gel
A 15% 6M urea poly-acrylamide gel was made by combining 13.125mL of 40%
acrylamide:Bis (19:1), 12.54g urea, 3.5mL of 10x TBE and DEPC H2O to bring the final
reaction mixture volume to 35mL. To this 35mL mixture was added 350µL of 10% APS
and 35µL TEMED (in order to polymerize the gel). The gel was then poured between two
cleaned glass plates and was allowed to sit for 30 minutes in order to polymerize. The gel
was pre-run in 1x TBE in H2ODEPC for 15 minutes at 230V. The wells were flushed
occasionally to get rid of urea. After a pre-run was completed the samples were loaded
into the gel and were run at 230V for 2 hours (until the dye front was just above the
bottom of the gel). After completion the gel was visualized by phosphoimager on x-ray
film.
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Quantitative RT-PCR for CTCF, BORIS, H19, IGF-2, Oct-4, C-myc, Nanog, Sox-2,
DLK, p16, RB, and CDX-2
(Performed as a service by Center for Functional Genomics, Albany, NY)
Nineteen hemangioma samples (4 proliferative, 10 quiescent, 5 involuting) and 4
endothelial cell control lines were RNA extracted as previously specified and subjected to
fluorescent quantitative RT-PCR using ABI Taqman primers that were previously
validated by the manufacturer. RNA was converted to first strand cDNA by use of the
RETROscript First Strand Synthesis Kit (Ambion, Austin, TX) and primed with oligo-dT
according to the manufacturers specifications. Taqman gene expression assays to
quantify gene expression were obtained from Applied Biosystems (Foster City, CA), and
are identified below.
Assay ID:

Gene Name:

Hs00902008_m1
Hs01005963_m1
Hs00540744_m1
Hs00895526_m1
Hs00905030_m1
Hs02387400_g1
Hs01053049_s1
Hs03005111_g1
Hs00171584_m1
Hs99999189_m1
Hs01078066_m1
Hs01078080_m1
Hs99999905_m1

CTCF
IGF2
CTCF-L (BORIS)
H19
C-myc
Nanog
Sox2
Oct4
DLK
p16
RB
CDX-2
GAPDH

Two-step Taqman-based quantitative RT-PCR was performed. First strand cDNA
was synthesized as described above, and the cDNA equivalent of 20 ng starting RNA was
then included as template in qPCR reactions. QPCR Reactions to detect gene expression
contained 1X Taqman Master Mix (Applied Biosystems) and 1X gene-specific assay
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reagents as recommended by the manufacturer (Applied Biosystems). All reactions were
run in triplicate.

Reactions that did not contain template cDNA were included as

negative controls
Reaction plates were processed on an Applied Biosystems 7900HT Sequence
Detection System. The AmpliTaq Gold polymerase was activated at 95oC for 10 min
followed by 40 cycles consisting of denaturation for 15 seconds at 95oC and annealing
and extension for 60 seconds at 60oC.
Amplification data was analyzed with the ABI Prism SDS 2.1 software (Applied
Biosystems). Relative quantification of gene expression was performed by the %%Ct
method.100 GAPDH expression served as an endogenous control to normalize expression
within each sample.
The student performed data analysis in collaboration with the Yale University
Department of Biostatistics. The nineteen cases were compared with the four controls
using a two-sample, two tailed, t-test, assuming unequal variances. The p-values were
ranked and compared with the Bonferroni correction for multiple comparisons.
Specifically, the p-values need to attain a level of significance was determined by the
following calculation: 0.05 / 22 = .00227, where 22 equals the number of comparisons.

MicroRNA Microarray
(Performed as a service by LC Sciences, Houston, TX)
This experiment consisted of nine hemangioma samples ages: 81, 165, 286, 299,
380, 590, 752, 1171, and 3626 days. The ages of samples were calculated from birth to
time of resection. In addition, two normal endothelial cell control lines were analyzed at
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passage 4: adult and neonatal HDMEC. Each probe was included on the chip seven times
and from these signals an average and standard deviation were calculated. P-values of the
t-test were calculated for any detected signal for one transcript between one sample and
another, those with values less than 0.01 were considered significant and were subjected
to unbiased cluster analysis.
The assay started from 2 to 5 $g total RNA sample, which was size fractionated
using a YM-100 Microcon centrifugal filter (from Millipore) and the small RNAs (< 300
nt) isolated were 3’-extended with a poly(A) tail using poly(A) polymerase.

An

oligonucleotide tag was then ligated to the poly(A) tail for later fluorescent dye staining;
two different tags were used for the two RNA samples in dual-sample experiments.
Hybridization was performed overnight on a $Paraflo microfluidic chip using a microcirculation pump (Atactic Technologies). On the microfluidic chip, each detection probe
consisted of a chemically modified nucleotide coding segment complementary to target
microRNA (from miRBase, 11.0 http://microrna.sanger.ac.uk/sequences/) and a spacer
segment of polyethylene glycol to extend the coding segment away from the substrate.
The detection probes were made by in situ synthesis using PGR (photogenerated reagent)
chemistry.

The hybridization melting temperatures were balanced by chemical

modifications of the detection probes. Hybridization used 100 µL 6xSSPE buffer (0.90 M
NaCl, 60 mM Na2HPO4, 6 mM EDTA, pH 6.8) containing 25% formamide at 34 °C.
After hybridization, detection used fluorescence labeling, using tag-specific Cy3 and Cy5
dyes.

Hybridization images were collected using a laser scanner (GenePix 4000B,

Molecular Device) and digitized using Array-Pro image analysis software (Media
Cybernetics). Data was analyzed by first subtracting the background and then
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normalizing the signals using a LOWESS filter (Locally-weighted Regression). For two
color experiments, the ratio of the two sets of detected signals (log2 transformed,
balanced) and p-values of the t-test were calculated; differentially detected signals were
those with less than 0.01 p-values.
Additional data analysis was performed at Yale University in the Department of
Biostatistics. The nine cases were compared with the two controls using a two-sample,
two tailed, t-test, assuming unequal variances. The p-values were ranked and compared
with the Bonferroni correction for multiple comparisons. Specifically, the p-values need
to attain a level of significance was determined by the following calculation: 0.05 / 886 =
.000056, where 886 equals the number of markers examined.

microRNA Pathway Analysis Using Ingenuity Software and MetaCore Software
(Performed as a service by Bioinformatics at Yale)
Data was first analyzed through the use of Ingenuity Pathways Analysis
(Ingenuity® Systems, www.ingenuity.com).

1. Network Generation
A data set containing gene identifiers and corresponding expression values was
uploaded into the application. Each gene identifier was mapped to its corresponding gene
object in the Ingenuity Pathways Knowledge Base. A 1.5-fold expression threshold, and
p-value <0.05 was set to identify genes whose expression was significantly differentially
regulated.

These genes, called focus genes, were overlaid onto a global molecular

network developed from information contained in the Ingenuity Pathways Knowledge
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Base. Networks of these focus genes were then algorithmically generated based on their
connectivity.

2. Functional Analysis of an Entire Data Set
The Functional Analysis identified the biological functions and/or diseases that
were most significant to the data set. Genes from the dataset that met the 1.5 fold
expression threshold, and p-value <0.05 and were associated with biological functions
and/or diseases in the Ingenuity Pathways Knowledge Base were considered for the
analysis. Fischer’s exact test was used to calculate a p-value determining the probability
that each biological function and/or disease assigned to that data set is due to chance
alone.

3. Functional Analysis of a Network
The Functional Analysis of a network identified the biological functions and/or
diseases that were most significant to the genes in the network. The network genes
associated with biological functions and/or diseases in the Ingenuity Pathways
Knowledge Base were considered for the analysis. Fischer’s exact test was used to
calculate a p-value determining the probability that each biological function and/or
disease assigned to that network is due to chance alone.

4. Canonical Pathway Analysis: Entire Data Set
Canonical pathways analysis identified the pathways from the Ingenuity Pathways
Analysis library of canonical pathways that were most significant to the data set. Genes

37

from the data set that met the 1.5 fold expression threshold, and p-value <0.05 and were
associated with a canonical pathway in the Ingenuity Pathways Knowledge Base were
considered for the analysis. The significance of the association between the data set and
the canonical pathway was measured in 2 ways: 1) A ratio of the number of genes from
the data set that map to the pathway divided by the total number of genes that map to the
canonical pathway is displayed. 2) Fischer’s exact test was used to calculate a p-value
determining the probability that the association between the genes in the dataset and the
canonical pathway is explained by chance alone.

5. Network/My Pathways Graphical Representation
A network/My Pathways is a graphical representation of the molecular
relationships between genes/gene products (See Image 15). Genes or gene products are
represented as nodes, and the biological relationship between two nodes is represented as
an edge (line). All edges are supported by at least 1 reference from the literature, from a
textbook, or from canonical information stored in the Ingenuity Pathways Knowledge
Base. Human, mouse, and rat orthologs of a gene are stored as separate objects in the
Ingenuity Pathways Knowledge Base, but are represented as a single node in the network.
The intensity of the node color indicates the degree of up- (red) or down- (green)
regulation. Nodes are displayed using various shapes that represent the functional class
of the gene product.
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Data was also analyzed using MetaCore™ software version 5.2 from GeneGo Inc.

MetaCore™ is an integrated software suite for functional analysis of experimental
data. The scope of data types includes microarray and SAGE gene expression, SNPs and
CGH arrays, proteomics, metabolomics, pathway analysis, Y2H and other custom
interactions. MetaCore™ is based on a proprietary manually curated database of human
protein-protein, protein-DNA and protein-compound interactions, metabolic and
signaling pathways and the effects of bioactive molecules in gene expression.
MetaCore™ uses 10 different network-generating algorithms and includes specificity
filters for tissues, functional processes, sub-cellular localization, interaction mechanisms,
and species.

Hemangioma Cell Culture
(Performed by the student)
Freshly resected hemangioma tissue was minced into 1mm cubes. A portion of
the sample was placed in collagenase and incubated at 37˚ C in 5% CO2 / 95% air for 20
minutes following mincing. Tissue sample not degraded by collagenase was divided
equally into three parts. One portion was suspended in 100mL modified TeSR1 basal
medium for maintenance of human embryonic stem cells (mTeSR1, StemCell
Technologies). A second portion was suspended in 100mL mTeSR1 with the addition of
20mL of 5x supplement (StemCell Technologies) containing recombinant human basic
fibroblast growth factor (rhbFGF) and recombinant human transforming growth factor !
(rhTGF !). A third portion was suspended in 100mL mTeSR1 with the addition of 20mL
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of 5x supplement, 10µL of basic fibroblast growth factor (bFGF, StemCell Technologies)
with a concentration of 0.500 mg/mL, and 50µL of heparin (concentration 100ng/mL).
These samples were then plated on a 12-well culture plate, 4 wells per sample, and
incubated overnight at 37˚ C. The sample treated with collagenase was then divided into
three portions as described above. One mL of each of the three collagenase samples, and
1 mL of each of the three non-collagenase samples were then plated on a six-well
BioFlex plate containing collagen IV membrane (Flexcell International Corp.) This was
then repeated on a six-well BioFlex plate containing elastin membrane (Flexcell
International Corp).
Additional tissue sample was cultured according to the method published by Xiao
et al.98 Tissue specimen was placed in standard culture medium consisting of Medium
199 (M-199; Gibco, Rockville, MD) supplemented with 200µg/mL streptomycin,
75µg/mL endothelial cell growth supplement (ECGS; Sigma, St. Louis, MO) and
50pg/mL of 17!-estradiol (Sigma).
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Summary of Methods:
Performed by Student:
•

Specimen Collection

•

RNA extraction

•

piRNA detection

•

Hemangioma cell culture

Performed as Services:
•

Quantitative RT-PCR of IGF-2, H19, BORIS, CTCF, DLK, Oct4, Sox2, Nanog,
C-myc, CDX-2 (Center for Functional Genomics)

•

microRNA microarray (LC Sciences)

•

microRNA pathway analysis using Ingenuity Software and MetaCore Software
(Bioinformatics at Yale)
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Additional Experiments to Complete:
This thesis represents a work in progress and additional experiments await completion in
order to continue to test the hypothesis that hemangiomas represent mesenchymal stem
cell tumors derived from pericytes. A list of anticipated experiments is below with
appropriate explanation in the discussion section:

•

Confirm expression of Oct-4, C-myc, Sox-2, and Nanog with western blot

•

Examine hemangiomas for expression of nestin and sox10 (markers of neural
crest derived cells)

•

Perform quantitative RT-PCR on samples for DLK, PDGFR-2, and NG2, PPAR-$

•

Using a lentivirus vector treat hemangioma cell cultures with siRNA to DLK to
show differentiation to adipocytes

•

Identify single nucleotide polymorphisms (SNPs) at the DLK gene locus. Treat
hemangioma cell cultures with thiazolidinediones (a class of anti-diabetic drugs
that are PPAR-$ receptor ligands and induce adipocyte differentiation) and
measure

time

to

conversion

from

hemangioma

tissue

to

adipose.
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Results:
Quantitative RT-PCR to Determine Expression Levels of: IGF-2, H19, CTCF, BORIS,
Oct-4, C-myc, Sox-2, Nanog, RB, p16, DLK, and CDX-2
We examined the transcription factors of “stemness” Oct-4, C-myc, Sox-2 and
Nanog in 19 hemangiomas (representing all three stages of growth) compared to control
adult endothelial cells, neonatal endothelial cells, human dermal endothelial cells and
human umbilical vein endothelial cells by quantitative RT-PCR. We found that all
hemangiomas expressed factors Oct-4, Sox-2, C-myc, and Nanog at levels higher than
endothelial cell controls (See Image 7). Taken individually these differences achieve
statistical significance with p-values < 0.05;

(See Image 8). Because multiple

comparisons were made, this must be taken into account using the Bonferroni correction
(0.05/22 = 0.00227). The new threshold for significance is 0.002, and none of the stem
cell transcription factors reach this corrected threshold for significance.
In addition to transcription factors known to be upregulated in embryonic stem
cells, we examined several genes implicated in the growth and pathogenesis of
hemangiomas. These genes included IGF-2 (mitogenic, pro-angiogenic, and growth
promoting), CTCF (universal transcription factor and regulator of IGF-2), RB (tumor
suppressor), p16 (tumor suppressor), and DLK (negative regulator of adipogenesis and
adipocyte maturation).
Our results confirm the increased IGF-2 produced by hemangiomas at a
statistically significant level of p < 0.001. IGF-2 is a pro-angiogenic and mitogenic factor
that has been implicated in the growth of hemangiomas.46 The limited number of samples
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we examined and the variability in IGF-2 production, however, prevented us from
differentiating the level of IGF-2 production between proliferating, plateau, and
involuting hemangioma samples. Our results also indicate that CTCF production is
increased by a factor of 4 in hemangiomas compared to controls (p-value <0.002). This
transcription factor binds to the IGF-2 locus and it is believed that increased levels of this
transcription factor lead to decreased levels of IGF-2.64 The transcription factor BORIS
was detectable, although at very low levels, in ten of nineteen samples.
RB is a widely expressed tumor suppressor protein that is dysfunctional in many
types of cancer. An initial hypothesis predicted that this protein would be downregulated
in hemangiomas given its role in arrest of the cell cycle. Surprisingly, the expression of
the tumor suppressor gene retinoblastoma (RB) was increased in hemangioma samples by
a factor of three compared to endothelial cell controls; and, this result was statistically
significant at the p < 0.001 level.
DLK is significant in that it represents a critical protein that is involved in the
control of adipocyte differentiation of pre-adipocytes. A mere two-fold increase in
expression of DLK was found to robustly prevent the conversion of 3LT3 pre-adipocytes
to adipocytes.36 A previous study46 demonstrated a decrease in DLK expression by five
fold during the hemangioma maturation process. The variability between our samples
was too great to detect a significant decrease in DLK expression during the hemangioma
maturation process. However, our results indicate that hemangiomas express DLK at a
level greater than 105 orders of magnitude compared to controls (See Image 7) and this
result is statistically significant at the p < 0.001 level. Thus, the very high levels of DLK,
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especially in the proliferating hemangiomas, argue for a role of this gene in the
suppression of fat conversion.
We also examined hemangioma samples for expression of CDX-2, a gene
normally expressed by the placenta. Previous studies have shown that CDX-2 is
sufficient to induce differentiation of embryonic stem cells down a trophoectoderm
lineage, which eventually forms the placenta. Furthermore, reciprocal inhibition between
CDX-2 in trophoectoderm and Oct3/4 in pluripotent cells is thought to be involved in
segregation of these cell lineages.101 We were unable, however, to detect the placental
specific transcription factor CDX-2 in any of our samples.

PiRNA Analysis
PiRNA analysis revealed that hemangiomas do not contain piRNA transcripts,
thus excluding the role of these molecules in regulation of hemangioma growth and
pathogenesis. Image 3 shows the absence of a piRNA band in all 7 hemangioma
specimens as well as the control sample of HUVEC.

MicroRNA Microarray Analysis
Data analysis generated a list of microRNAs expressed in hemangiomas at a level
statistically significant from the controls (adult and neonatal HDMEC). This list is
displayed in Image 9. In addition, microRNA profiles of the 9 samples and 2 controls
were clustered (average linkage, correlation similarity). The results of this analysis are
displayed in Images 11 and 12. However, when the microRNA expression profiles of the
three proliferating hemangioma samples were compared to the three involuting samples
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there was no statistically significant difference in expression profiles. The reason for this
may be attributable to our small sample size and the large number of microRNAs
analyzed. Given the large number of comparisons made between specimens and controls,
results required a p-value of < 0.000056 in order to attain significance, when using the
Bonferroni correction (0.05/886 = 0.000056).
Despite this high threshold for significance, our microarray data indicates that
microRNAs associated with mesenchymal stem cells (miR-143, miR320a, miR320c, let7c) are upregulated in hemangiomas compared to controls. Of particular interest, miR143 was significantly upregulated in this group of tumors by over 100x compared to
controls (p< 0.000056). Increased levels of miR-143 have been observed in
differentiating adipocytes, and inhibition of miR-143 has been shown to effectively
inhibit adipocyte differentiation.80 MiRNA 195, a microRNA known to target DLK, was
also upregulated more than 25x in hemangioma samples.
Both let-7c and let-7g have increased expression levels in hemangiomas
compared to controls. Let-7g is upregulated 2x and let-7c is upregulated 1.5x in
hemangiomas compared to controls (p<0.000056). Let-7 was originally identified in C.
elegans in a screen seeking genes that regulate developmental timing.102 Loss of function
of this miRNA prevents normal transition of late larval to adult cell fates. There are 12
let-7 homologs in the human genome, organized in eight distinct clusters. At least four of
these clusters are contained within regions known to be frequently deleted in diverse
human

malignancies.103

Furthermore,

two

studies

have

documented

frequent

downregulation of let-7 family members in lung cancer associated with poor
prognosis.104, 105

46

Analysis of hemangioma specimens also revealed decreased expression of miR106a by 2x compared to controls. The retinoblastoma (RB1) 3’UTR is found to be
functionally interactive with miR-106a.106 The biological significance of this proven
miRNA::mRNA interaction is reinforced by previous reports showing that RB1 gene is
normally transcribed in colon cancers whereas various fractions of cells do not express
RB1 protein.107 This finding suggests a post-transcriptional mechanism for regulation of
RB1, which could possibly be explained by the concomitant overexpression of miR-106a
detected in colon carcinoma.106

MicroRNA Pathway Analysis
Ingenuity software helped identify key molecules and pathways that could
potentially play a role in the pathogenesis of hemangiomas. Of 603 microRNAs in the
initial list 466 were recognized by Ingenuity and 150 were eligible for network analysis.
With a 1.5-fold expression threshold and p-value <0.05, 65 miRNAs were network
analysis eligible. The top biological functions implicated in hemangioma pathogenesis
were cancer and reproductive system disease. Both the cardiovascular and nervous
systems were implicated as developmental systems involved in hemangioma
pathogenesis. A complete list is shown in Image 13.
When these biological functions are organized into networks and then ranked
according to the –log of the p-value, the network that includes cancer, reproductive
system disease, cellular growth and proliferation is most significantly involved. A
complete list of the networks implicated in hemangioma pathogenesis is shown in Image
14.
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The Cancer, Reproductive System Disease, Cellular Growth and Proliferation
Network is displayed in the appendix (See Image 15).

In-depth analysis of these

networks falls outside the scope of our hypothesis because the vast majority of
transcription factors and miRNAs pictured have yet to be directly linked to
hemangiomas. However, this image is included to demonstrate the data generated by this
analysis and to show how the creation of such networks can elucidate the transcription
factors and second messengers that function as downstream targets of the miRNAs
differentially expressed in hemangiomas. The identification of key pathways involved in
hemangioma pathogenesis will prove to be important in developing new therapeutics that
more specifically target hemangiomas than the ubiquitously prescribed corticosteroids
that now comprise the mainstay of treatment for these lesions.
Pathway analysis was also performed using MetaCore software and the results of
this analysis are more directly relevant to evaluation of our hypothesis that hemangiomas
represent tumors of mesenchymal stem cell origin. The MetaCore software generates
networks centered on specific transcription factors and suggests which transcription
factors regulate the indicated genes. Members of the target list are shown with a blue or
red circle next to their icons, where red indicates upregulation and blue indicates
downregulation in the experiment. Red lines indicate inhibition, and green lines
activation, as indicated from the literature.
Image 16 shows the relationship between C-myc and numerous miRNAs. Of the
miRNAs pictured only let-7c and let-7a-1 regulate C-myc expression, and both have an
inhibitory effect. The rest of miRNAs depicted are downstream targets of C-myc. Similar
images are generated for p53 and Sox2 (See Image 17). These images show how the
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differentially expressed microRNAs in hemangiomas interact with various other
transcription factors.
Another function of MetaCore allows for Interactome analysis, which was
performed with the miRNA genes that were 1.5x upregulated (at p<0.05), and combined
with genes implicated in hemangioma pathogenesis. This analysis begins by identifying
genes found in the literature or reported in the MetaCore disease database as associated
with hemangiomas (See Image 18). These genes were then added to the miRNA gene set
to strengthen the network analysis.
The Interactome analysis table (See Image 19) shows transcription factors having
a significantly high number of outgoing connections (i.e., connections of the type
“regulates”) to members of the target list. The False Discovery Rate parameter for the list
was set at 0.05 (i.e. 1 out of 20 are likely false). Those transcription factors that have a
small number of connections (like r=1) to list members are the least reliable ones.
Image 21 shows a network of miRNAs and known hemangioma related genes.
This is most useful image in highlighting the key molecules involved in the regulation of
hemangioma-related genes. The threshold for differential expression of miRNA is set to
4x in order to increase the specificity of the pathways highlighted. Image 22 highlights
the shortest pathway between hemangioma related genes and differentially expressed
miRNAs.
MetaCore then uses the list of differentially expressed miRNAs and a list of
known hemangioma genes derived from the scientific literature to develop a list of
disease processes that share biomarkers with hemangiomas. The results of this analysis
are displayed in Images 23 and 24. Image 23 uses only the list of differentially expressed
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miRNAs, while Image 24 combines these miRNAs with known hemangioma related
genes.
Similarly to Ingenuity, MetaCore identified uterine neoplasms and disease as the
processes sharing most pathways and biomarkers with hemangiomas. Image 25 gives a
graphical representation of the pathways shared by hemangiomas and uterine disease and
the key players in these pathways. As highlighted miR-21 and let-7a-1 are both involved
as well as the transcription factors CTCF, BORIS, and C-myc, all of which exert
influence on IGF-2, a key regulator of hemangioma proliferation and growth.

Hemangioma Cell Culture
None of the hemangioma tissue specimens placed in embryonic stem cell medium
demonstrated growth or vascular sprouting in culture after incubation for seven days. The
hemangioma tissue that was placed in standard culture medium supplemented with
200µg/mL streptomycin, 75µg/mL endothelial cell growth supplement demonstrated
growth at the one-week mark. Growth became prominent at the 2-& week mark.
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Summary of Results:

•

Hemangiomas express the stem cell related transcription factors Oct-4, Sox-2, Cmyc, and Nanog at levels higher than endothelial cell controls. This is significant
at the p < 0.05 level but not at the 0.002 level required by the Bonferroni
correction for multiple comparisons.

•

Hemangiomas express IGF-2, RB, and DLK at a level higher than endothelial cell
controls (p < 0.001).

•

Hemangiomas do not express the placental transcription factor CDX-2.

•

Hemangiomas do not contain piRNA transcripts.

•

Hemangiomas express the following miRNAs (miR-143, miR320a, miR320c, let7c) that are associated with mesenchymal stem cells at levels higher than controls
(p < 0.000056).

•

miR-143 is upregulated in hemangiomas more than 100x compared to controls (p
< 0.000056). Increased levels of miR-143 have been observed in differentiating
adipocytes and inhibition of miR-143 has been shown to effectively inhibit
adipocyte differentiation.

•

miR-195, known to target DLK, is upregulated more than 25x compared to
controls (p < 0.000056).

•

Embryonic stem cell media supplemented with recombinant human basic
fibroblast growth factor (rhbFGF) and recombinant human transforming growth
factor ! (rhTGF-!) did not lead to vascular sprouting and culture of hemangioma
tissue.
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Discussion:

Hemangioma Placenta Connection
While it is no longer believed that hemangiomas represent embolized placental
tissue, the similarities between the two tissues should help us think about hemangiomas
as tumors composed of cells performing a barrier function. Just because hemangiomas
are not placental tissue does not mean that we should abandon investigation process into
the overlap between them. Two independent microRNA pathway analysis programs,
Ingenuity and MetaCore, identified reproductive system disease (Uterine Disease in
MetaCore) as an important network regulated by microRNAs differentially expressed by
hemangiomas (See Images 15 and 25). MicroRNA 21 is predicted to be a critical player
in both of these networks, and microarray analysis shows upregulation of this molecule in
hemangiomas of all stages of growth.
A potential oncogenic role for miR-21 was first discovered in a screen for
abnormally expressed miRNAs in glioblastoma.108 Using an expression array and
northern blotting, miR-21 was demonstrated to be consistently upregulated in human
glioblastoma tumor tissues, primary tumor cultures, and established glioblastoma cell
lines relative to normal fetal and adult brain tissue and primary cultured neurons and
astrocytes. Knockdown of miR-21 in glioblastoma cell lines led to activation of caspases
and a corresponding induction of apoptotic cell death. Support for a more general role of
miR-21 in cancer was recently observed with widespread overexpression of miR-21 in
diverse tumors including those from the breast, colon, lung, pancreas, stomach, and
prostate.106
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Our research has uncovered further differences between placental tissue and
hemangiomas with the fact that hemangiomas do no express the placental specific
transcription factor CDX-2. This transcription factor is involved in the differentiation of
embryonic stem cells down a trophoectoderm lineage,101 which eventually develops into
the placenta. The question still remains why do hemangiomas share so many markers
with placental tissue? The answer to this may lie in the fact that placental tissue contains
a large population of pericytes.
Additional connections between placental tissue and hemangiomas remained to be
discovered. Previous work by Narayan’s lab identified that hemangiomas express the
pathologic protein BORIS, which is normally only expressed in the testis. BORIS is a
member of the cancer-testis (CT) gene family that comprises genes normally expressed
only in testis, but abnormally activated in different malignancies. Its normal role in the
testis consists of resetting genome-wide DNA methylation during spermatogenesis.
Given this localization of BORIS to the testis, we hypothesized that other testis-specific
regulatory proteins, specifically piRNAs, could be expressed in hemangiomas. However,
our results indicate that piRNAs are not present in hemangiomas and therefore do not
play a role in the growth or pathogenesis of these lesions.

Hemangiomas as Mesenchymal Stem Cell Tumors
It has long been thought that hemangiomas are endothelial cell tumors. One group
has shown that endothelial progenitor cells are present in hemangiomas.27 However, not
all samples (eleven of twelve) demonstrated CD133+/CD34+ endothelial progenitor
cells. Furthermore, no such endothelial progenitor cells were identified in involuting
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hemangiomas. If hemangiomas were in fact endothelial cell tumors, one would expect all
hemangioma specimens to contain endothelial progenitor cells, cells which are present at
the start of the tumor and persist throughout the lifecycle of the tumor.
These studies examined hemangioma clonality using X-linked human androgen
receptor gene assay (HUMARA) analysis. One study analyzed cells grown in culture
from seven patients, and all showed a skewing toward a single allele.29 A subsequent
study analyzed intact tissue without selection of cells and found some degree of allelic
loss in 12 of 14 samples.30 These two independent investigations suggest that
hemangiomas arise as a consequence of clonal expansion from a single cell, however, it
is possible that sampling constraints biased these results. It is notable that 2 of the 14
samples did not show allelic loss, an argument against endothelial cell clonality in
hemangiomas.
It was recently demonstrated that a population of stem cells exist within
hemangiomas.31 These cells, termed hemangioma mesenchymal stem cells (Hem-MSCs),
were isolated from 14 proliferating and five involuting hemangiomas by taking advantage
of mesenchymal stem cells’ selective adhesion to plastic bacteriologic dishes.32 These
Hem-MSCs exhibited a random pattern of X-inactivation indicating that these cells are
not clonally derived. Authors of this study hypothesized that these mesenchymal stem
cells originated in the bone marrow and through selective homing arrived at the site of
the developing hemangioma. A recent lineage study shows, however, that pericytes are
the source of these mesenchymal stem cells.35
Even more intriguing is the possibility that the endothelial cells present in
hemangiomas arise from mesenchymal stem cells. If this were the case, a single cell type
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could explain the pathogenesis of these lesions. One group identified a population of cells
(CD34+/CD31-/CD45-) from the stromovascular portion of adipose tissue that could
differentiate into endothelial cells.109 Another group found a similar population of cells
(CD31-/CD34-/CD106-/VCAM-/fetal liver kinase+) from adipose tissue that expressed
endothelial markers when cultured with VEGF.110 Given that this population of
mesenchymal stem cells can differentiate into endothelial cells the causative defect in
hemangiomas may reside within this population of cells which then gives rise to a
proliferation of endothelial cells.
Even if mesenchymal stem cells are not the source of cells that differentiate into
endothelial cells, additional studies have shown that these multipotent mesenchymal stem
cells of perivascular origin serve both structural and functional roles in interactions with
endothelial cells.33 Hemangiomas may proliferate as a result of the unique interaction
between mesenchymal stem cells and endothelial cells in response to hypoxia in the local
environment or other potential causes.
By using quantitative RT-PCR, we demonstrated that hemangiomas specimens
express transcription factors and genes known to play a role in the maintenance of stem
cell pluripotency at a level greater than control endothelial cells. Specifically,
transcription factors Oct-4, Sox-2, C-myc, and Nanog are increased. This corroborates an
earlier study that identified mesenchymal stem cells within hemangioma tissue that are
distinct from endothelial progenitor cells.31
We chose to analyze transcription factors based on previous studies that identified
Oct-4,111,112 Sox-2,113 C-myc, and Nanog114 as factors that play a role in the maintenance
of pluripotency in both early embryos and embryonic stem cells. These factors were
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selected for analysis because Takahashi and Yamanaka demonstrated that adult fibroblast
cells can be reprogrammed into pluripotent stem cells by the induction of four critical
factors: Oct3/4, Sox2, C-myc, and Klf4.112 In addition, Oct4 plays a critical role in the
establishment and maintenance of pluripotent cells in a pluripotent state.115
Expression of Sox2, Oct-4, Nanog, and C-myc at levels higher than control
endothelial cells does not confirm that hemangiomas represent tumors derived solely
from mesenchymal stem cells. However, the expression of these factors does confirm that
there is a population of stem cells within hemangioma tissue and gives further evidence
to the role of this population of cells within hemangiomas.
A microRNA microarray lends further support to this hypothesis. A previous
study116 has identified a set of microRNAs associated with mesenchymal stem cells. Of
these miRNAs our analysis indicates that miR-143, miR320a, miR320c, and let-7c (all
identified in mesenchymal stem cells) are upregulated in hemangioma tissue in all stages
of growth.
Given

that

a

population

of

mesenchymal

stem

cells

(SH2+/CD105+/SH3+/SH4+/CD90+/CD29+/smooth muscle #–actin+/CD133+/CD45/CD14-/CD34-/CD31-)" exists within hemangiomas, it is important to better characterize
the nature of these cells. The first step towards this will be identifying the specific cell
markers of this population of cells. To date the best method for identifying the pluripotent
stem cell population found in the stromovascular portion of adipose tissue is using the
profile: CD34+/CD31-/CD45-/CD144-, and 95% of this population of cells co-express
mesenchymal cell markers (CD10, CD13, CD90) and surface markers used to identify
The CD34 positivity of this population of cells is uncertain because it has been shown that CD34+ is
downregulated in culture (117).
"
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pericytes (NG2 and PDGFR).33 In future experiments it will be helpful to try and isolate
this specific population of cells from hemangiomas.

Pericytes are the origin of mesenchymal stem cells
We are just beginning to understand the relationship between pericytes and
mesenchymal stem cells. Recently, it has been demonstrated that pericytes are the
population of cells that give rise to mesenchymal stem cells that then develop into
adipocytes.35 It stands to reason that if hemangiomas are mesenchymal stem cell tumors,
then they have likely developed from pericyte origins. At the time of completion of this
thesis experiments to examine the recognized markers of pericytes (PDGFR and NG2) in
hemangioma specimens are pending. Hemangioma pathologic specimens will be stained
for PDGFR and NG2 as well.
Pericytes of the head and neck are derived from neural crest while pericytes in the
rest of the body derive from mesoderm. In order to investigate the potential neural crest
origins of hemangiomas we plan to analyze samples for nestin and sox10, which are
considered to be the best markers of neural crest-derived cells.

Regulation of Adipogenesis in Hemangiomas
As we begin to develop an understanding of the role of mesenchymal stem cells in
hemangiomas, it is important to identify those genes responsible for the progression and
development of the tumor. One gene that holds great promise is DLK, also known as
Pref-1. DLK is a cell surface protein in the epidermal growth factor family36 that
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functions as a negative regulator of adipocyte differentiation. A previous study has shown
that DLK is decreased five fold during the hemangioma maturation process.46 Our results
confirmed that DLK is increased in hemangiomas compared to controls, but there was too
much variability between groups to say with certainty whether DLK expression is
decreased in involuting hemangiomas compared to proliferating specimens.
The results of our microRNA microarray also show that miR-143 is increased in
hemangiomas compared to controls. This is of particular interest because increased levels
of miR-143 were observed in differentiating adipocytes, and inhibition of miR-143 has
been shown to effectively inhibit adipocyte differentiation.80
DLK may be a potential therapeutic target in the treatment of hemangiomas.
Downregulation of DLK, possibly through the use of siRNA, could hasten the
development of hemangiomas into fibroadipose tissue. In order to test this hypothesis we
plan to treat hemangioma cell cultures with siRNA to DLK using a lentivirus vector, to
determine if this speeds progression of cells into adipose tissue.
Along these lines of investigation we also plan to identify single nucleotide
polymorphisms at the DLK gene locus. Freshly resected hemangioma specimens will be
genotyped for these polymorphisms and then grown in culture. Once in culture, samples
will be treated with thiazolidinediones, a class of anti-diabetic drugs that are peroxisome
proliferator-activated receptor $ (PPAR-$) ligands that induce adipocyte differentiation
and increase the expression of PPAR-$ protein. We will then measure time to conversion
from hemangioma tissue to adipose and correlate that with DLK polymorphisms.
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Conclusion:
The results of our investigation do not conclusively implicate mesenchymal stem
cells as the cells of origin of hemangiomas. However, we have demonstrated that
hemangiomas express genes involved in the maintenance of stem cell pluripotency and
express microRNAs transcripts that are markers of mesenchymal stem cells at a level
significantly greater than endothelial cell controls. Important pieces of evidence are still
necessary to prove or disprove our hypothesis and several of these experiments are
pending. We must demonstrate that hemangiomas express markers of pericytes (NG2,
PDGFR-!). We must demonstrate that hemangiomas on the head and neck are of a neural
crest origin. Most importantly we must isolate the implicated cells of origin and show
that they can reconstitute hemangiomas in a culture-based model.
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Marker
DLK

Description
Also known as Pref-1, marker of pre-adipocytes, and cell
surface receptor in the epidermal growth factor family

Glut-1

Glucose transporter normally expressed in the
microvascular endothelium of blood-tissue barriers such as
brain, retina, placenta, and endoneurium

NG2

Neural/glial cell 2, also known as chondroitin sulfate
proteoglycan, is a proteoglycan associated with pericytes
during vascular morphogenesis; a marker of pericytes

PDGFR

Platelet derived growth factor receptor, a marker of
pericytes

PPAR-gamma

Expressed by pericytes and adipocytes

sFlt-1

Soluble form of the VEGF transmembrane receptor

SH2

Also known as CD105, a surface marker of hemangioma
derived MSCs along with SH3, SH4, CD90, CD29, CD133,
smooth muscle actin

CD14

Hematopoietic marker

CD31

Hematopoietic/endothelial marker

CD34

Marker of endothelial progenitor cells along with CD133,
also found on MSCs; downregulated in culture

CD45

Hematopoietic marker

CD133

Also known as AC133, a marker of endothelial progenitor
cells along with CD34

CD146

Also known as S-endo1, Mel-CAM, Muc18, or gicerin, an
endothelial marker found at the surface of pericytes
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Age in Days

RE

+/-

Adult Endothelial Control

0

1.00

0.02

Adult Endothelial Control

0

Neonatal Endothelial Control

0

0.99

0.02

Human Umbilical Vein Endothelial Control

0

1.19

0.07

Human Dermal Endothlelial Control

0

1.4

0.29

81

2.05

0.04

Neonatal Endothelial Control
Human Umbilical Vein Endothelial
Control
Human Dermal Endothlelial
Control

81
95

Proliferating Hemangioma

Sample

Age in Days

RE

+/-

0

1.00
0.52

0.03
0.03

0

0.00

0.00

0

0.00
308974.72
70988.3
153060.6
596991.60
369600.56
1119257.50
214070.92
69511.45
81457.12
64348.36
164881.06
126015.95
567857.56
43438.04

0.00
11193.45
3396.23
10311.93
24691.21
14907.02
153168.75
8838.76
2480.54
2784.75
2082.9
22057.23
7204.07
35369.21
1599.01

716259.50
94.47
31124.69
2330.59
560208.30

176958.58
16.14
1053.16
165.33
56309.02

Proliferating Hemangioma

95

6.54

0.27

Proliferating Hemangioma

Proliferating Hemangioma

95

3.61

0.32

Proliferating Hemangioma

Proliferating Hemangioma

165

1.91

0.06

Proliferating Hemangioma

95
165

Plateau Hemangioma

286

2.63

0.02

Proliferating Hemangioma

Plateau Hemangioma

299

2.87

0.33

Plateau Hemangioma

286

Plateau Hemangioma

299

Plateau Hemangioma

380

Plateau Hemangioma

418

Plateau Hemangioma

420

Plateau Hemangioma

547

Plateau Hemangioma

590

Plateau Hemangioma

635

Plateau Hemangioma

752

Plateau Hemangioma

380

1.93

0.07

Plateau Hemangioma

418

7.06

0.33

Plateau Hemangioma

420

6.39

0.22

Plateau Hemangioma

547

6.36

0.41

Plateau Hemangioma

590

1.81

0.20

Plateau Hemangioma

635

6.7

0.18

Plateau Hemangioma

752

1.85

0.11

Plateau Hemangioma

760

7.33

0.65

Involuting Hemangioma

1171

1.83

0.46

Involuting Hemangioma

1277

1.34

0.06

Involuting Hemangioma

1520

4.02

0.57

Involuting Hemangioma

2138

0.5

Involuting Hemangioma

3626

4.18

Plateau Hemangioma

760

Involuting Hemangioma

1171

Involuting Hemangioma

1277

Involuting Hemangioma

1520

0.02

Involuting Hemangioma

2138

0.34

Involuting Hemangioma

3626
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Sample
Adult Endothelial Control
Neonatal Endothelial Control
Human Umbilical Vein Endothelial Control
Human Dermal Endothlelial Control
Proliferating Hemangioma
Proliferating Hemangioma
Proliferating Hemangioma
Proliferating Hemangioma
Plateau Hemangioma
Plateau Hemangioma
Plateau Hemangioma
Plateau Hemangioma
Plateau Hemangioma
Plateau Hemangioma
Plateau Hemangioma
Plateau Hemangioma
Plateau Hemangioma
Plateau Hemangioma
Involuting Hemangioma
Involuting Hemangioma
Involuting Hemangioma
Involuting Hemangioma
Involuting Hemangioma

Age in Days
0
0
0
0
81
95
95
165
286
299
380
418
420
547
590
635
752
760
1171
1277
1520
2138
3626

Oct4
RE
1.00
0.41
14.72
2.45
19.45
73.16
91.97
9.43
15.96
19.18
4.34
90.6
27.17
0.00
78.65
337.05
18.06
107.94
32.69
8.61
47.69
6.53
28.60

+/0.04
0.04
1.64
1.06
1.08
8.08
8.73
0.46
0.57
2.55
0.09
14.54
2.04
0.00
4.27
51.12
1.10
16.56
8.19
0.96
5.91
0.58
1.11

Sox2
Nanog
RE
+/RE
+/1.00
0.10
1.00
0.12
0.00
0.00
0.78
0.03
195.26
7.79
29.4
2.1
0.00
0.00
0.00
0.00
25.24
5.99
94.17
4.17
575.63 85.44 381.83 44.39
396.01 133.29 237.28 18.88
11.22
1.28
88.24
4.82
74.31
9.72
282.30
6.85
20.96
2.56
176.75 21.05
295.36 12.48
45.27
3.95
249.72 48.03 264.62 11.99
0.00
0.00
658.75 42.09
1787.73 247.59 336.11 36.82
0.00
0.00 2012.48 156.71
882.22 28.58 3072.5 165.83
78.30
9.29
127.31
7.69
442.11 108.44 697.57 39.62
104.41 27.44 392.09 95.60
511.79
63.8
14.96
0.74
327.01 88.11 453.72
8.66
963.52 137.96 33.11
0.95
317.89 30.83 339.93 35.40

C-Myc
RE
+/1.00
0.06
1.88
0.04
0.00
0.00
0.00
0.00
6.49
0.16
1.00
0.02
0.00
0.00
0.00
0.73
12.23
0.12
8.76
1.08
5.76
0.07
1.17
0.09
1.88
0.03
0.78
0.04
35.65
3.07
0.00
0.00
4.13
0.25
1.77
0.08
12.92
3.21
0.36
0.01
0.62
0.03
0.03
0.00
5.43
0.48
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Sample
Adult Endothelial Control
Neonatal Endothelial Control
Human Umbilical Vein Endothelial Control
Human Dermal Endothlelial Control
Proliferating Hemangioma
Proliferating Hemangioma
Proliferating Hemangioma
Proliferating Hemangioma
Plateau Hemangioma
Plateau Hemangioma
Plateau Hemangioma
Plateau Hemangioma
Plateau Hemangioma
Plateau Hemangioma
Plateau Hemangioma
Plateau Hemangioma
Plateau Hemangioma
Plateau Hemangioma
Involuting Hemangioma
Involuting Hemangioma
Involuting Hemangioma
Involuting Hemangioma
Involuting Hemangioma

Age in Days
0
0
0
0
81
95
95
165
286
299
380
418
420
547
590
635
752
760
1171
1277
1520
2138
3626

IGF-2
RE
+/1.00
0.05
0.42
0.01
16.46
2.02
0.16
0.05
11175.69 244.15
5340.17
513.55
6310.24
144.79
7008.52
197.56
7104.24
179.33
9342.13 1080.98
3725.51
151.69
8038.53
228.03
12583.25 209.86
6505.15
215.46
32721.81 2518.83
11762.76 972.26
10283.14 585.44
11517.89 341.06
13263.79 3242.72
29.93
1.49
1162.69
35.52
66.49
3.2
21173.78 2370.70

CTCF
RE
+/1.00
0.04
0.86
0.03
3.32
0.17
2.49
0.22
2.94
0.06
9.64
0.18
10.57
0.41
2.81
0.08
3.99
0.05
7.41
0.93
2.83
0.08
31.7
1.59
13.2
0.51
0.00
0.00
6.30
0.41
16.68
0.71
3.42
0.29
15.92
1.09
8.51
2.08
2.73
0.13
7.46
0.52
1.48
0.06
15.67
0.90

H19
RE
0.00
0.00
0.00
0.00
1.35
0.00
0.00
0.40
0.29
1.00
0.17
0.00
0.00
0.00
0.25
0.00
0.18
0.00
0.86
0.00
0.00
0.00
0.13

+/0.00
0.00
0.00
0.00
0.09
0.00
0.00
0.02
0.05
0.23
0.03
0.00
0.00
0.00
0.00
0.00
0.01
0.00
0.23
0.00
0.00
0.00
0.02

BORIS
RE
+/0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.07
0.00
0.00
0.00
0.00
0.00
0.40
0.01
1.01
0.07
1.00
0.17
0.75
0.13
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.79
0.09
0.77
0.20
0.5
0.05
0.77
0.20
0.00
0.00
0.00
0.00
0.00
0.00
2.34
0.57
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Group Statistics
sample
or
control
RB Expression

p16 Expression

DLK Expression

Oct4 Expression

Sox2 Expression

Nanog Expression

C-myc Expression

Igf2 Expression

CTCF Expression

N

Mean

Std. Deviation

Std. Error
Mean

sample

19

3.7321

2.27742

.52248

control

4

1.1450

.19330

.09665

sample

19

3.2800

1.76556

.40505

control

4

2.4925

2.43641

1.21820

sample

19

276866.9100

3.04586E5

69876.81214

control

4

.3800

.48056

.24028

sample

19

53.5305

76.54509

17.56065

control

4

4.6450

6.77114

3.38557

sample

19

371.7595

447.44164

102.65015

control

4

49.0650

97.46447

48.73224

sample

19

510.9995

762.19721

174.86003

control

4

7.7950

14.40972

7.20486

sample

19

5.2095

8.43447

1.93500

control

4

.7200

.90569

.45284

sample

19

9427.1426

7615.04047

1747.01010

control

4

4.5100

7.97440

3.98720

sample

19

8.5926

7.61084

1.74605

control

4

1.9175

1.19092

.59546

9%

!"#$%$&#'()*#'+%,%(-.((/0#*$"#$12(345673(89:;2%%,-*(<212'%(

=(

!"#$%&'()*+,$-./012-3*%$*4%56$-./012-3*7%8,1$-3*2%*7%62$%0)*
miRNA

Expression Compared to Controls

hsa-miR-320c

Decreased

hsa-miR-299-5p

Decreased

hsa-miR-320a

Decreased

hsa-miR-106a

Decreased

hsa-miR-126

Increased

hsa-miR-517a

Increased

hsa-miR-517b

Increased

hsa-miR-195

Increased

hsa-miR-152

Increased

hsa-miR-1308

Increased

hsa-miR-143

Increased

hsa-miR-151-3p

Increased

hsa-miR-17

Increased

hsa-miR-26b

Increased

hsa-let-7g

Increased

hsa-miR-199a-3p

Increased

hsa-miR-145

Increased

hsa-miR-1323

Increased

hsa-miR-145

Increased

hsa-let-7c

Increased

hsa-miR-21

Increased

hsa-miR-27a

Increased

hsa-miR-1238

Increased

hsa-miR-516b

Increased

hsa-miR-424

Increased

hsa-miR-522

Increased

hsa-miR-23b

Increased

hsa-miR-30e

Increased

:;<10/-*=*>?>>>>@A*B%$*100*8"&'()*0")2-3*

9*

!"#$%&'()*+",-$-./0112*345$-))-6*".*7-80.9"%80)*

miRNA
hsa-miR-320c

S01 – 299
days

S02 - 1171

S03 - 752

S04 - 380

S05 - 81

S06 - 3626

S07 - 590

S08 - 286

S09 - 165

S10 - Adult

S11 - Neonatal

Averaged
Signal

Averaged
Signal

Averaged
Signal

Averaged
Signal

Averaged
Signal

Averaged
Signal

Averaged
Signal

Averaged
Signal

Averaged
Signal

Averaged
Signal

Averaged
Signal

2,523

2,099

2,227

2,051

5,116

1,813

2,091

2,444

2,168

8,777

9,007

hsa-miR-299-5p
hsa-miR-320a
hsa-miR-106a
hsa-miR-126
hsa-miR-517a
hsa-miR-517b
hsa-miR-195
hsa-miR-152
hsa-miR-1308
hsa-miR-143

71
2,729
1,466
33,777
15,488
13,095
17,463
1,734
5,567
16,484

143
2,261
771
27,775
14,731
11,903
16,937
1,140
3,043
12,837

72
2,343
920
31,183
11,029
9,829
18,984
1,756
2,355
18,717

100
2,073
1,078
31,147
14,639
12,034
16,854
1,508
682
15,233

148
5,792
876
37,147
13,220
12,860
8,154
1,650
2,504
25,105

70
1,884
1,259
34,761
7,615
6,421
19,179
2,025
461
16,051

119
2,258
661
30,094
12,725
11,051
15,630
1,352
7,489
12,195

111
2,368
1,505
33,915
11,341
9,261
17,371
1,529
297
13,961

150
2,174
1,244
30,145
15,407
13,233
16,912
1,334
1,689
14,998

323
9,048
2,430
18,571
106
132
529
433
14,134
51

319
9,384
2,392
17,781
229
250
605
401
13,322
230

hsa-miR-151-3p
hsa-miR-17
hsa-miR-26b
hsa-let-7g

780
1,603
19,662
17,303

361
835
23,339
18,409

682
1,039
21,834
15,822

408
1,213
21,485
16,696

1,117
935
8,862
9,198

434
1,313
25,726
17,300

467
650
21,033
16,073

472
1,645
22,603
16,611

471
1,303
19,095
15,576

1,856
2,689
2,646
7,468

1,758
2,825
1,012
6,997

hsa-miR-199a-3p
hsa-miR-145
hsa-miR-1323
hsa-miR-145
hsa-let-7c
hsa-miR-21
hsa-miR-27a
hsa-miR-1238
hsa-miR-516b
hsa-miR-424
hsa-miR-522
hsa-miR-23b
hsa-miR-30e

13,729
12,871
7,471
12,871
41,779
26,068
9,873
41
3,801
6,514
2,192
17,195
1,500

13,044
10,978
8,094
10,978
34,520
17,224
10,233
31
3,602
4,575
2,660
20,103
1,283

17,100
20,338
6,790
20,338
31,714
24,874
9,910
55
3,265
4,459
1,721
19,544
1,238

14,238
18,923
9,722
18,923
33,236
26,178
10,545
31
4,021
5,923
2,380
22,609
1,382

8,640
33,129
13,136
33,129
29,602
45,450
3,755
61
5,226
3,174
2,220
18,947
320

13,540
21,896
4,980
21,896
32,934
19,240
9,024
41
1,113
2,917
1,282
25,363
1,590

11,911
20,220
7,742
20,220
36,362
18,898
9,454
36
3,746
3,849
2,366
23,866
1,427

14,504
14,934
8,853
14,934
41,166
23,072
10,173
47
3,322
7,070
2,034
21,553
1,842

13,825
17,926
14,050
17,926
33,698
30,768
7,340
22
5,797
8,222
3,333
21,923
1,200

2,637
130
120
130
19,542
1,273
2,181
126
66
62
81
14,634
211

1,650
398
344
398
23,402
2,403
1,402
133
184
119
317
14,320
219
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34*
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34"1.6"*".$--"-.,(.,4".#'>?0.
&"%".2",.,(.2,*"%&,4"%.,4".%",6(*@.
$%$+12'2=.

03>A3B8C.
0%&'(7('"D%.E.
0F<$7(*'%.G.
HI9.
HJ>IK.
939L.
9M9>N.
9+<2,"*'%.
I/L)E.
I3/0O.
I3/0P.
QIRE.
STPB)G.
?L)03GU?L039EV.
?L)03EU?L039GV.
?L)03WU?L039NV.
?L)03NU?L039WV.
?L)03O.
?"7*'+12'%.
3IB.
3IBE.
PB/L>)G.
PB/L>)E.
P!S.
X$;G..

GC.

!"#$%&'#()$*+"&,-./.*
Object name

SP1
SP3
ETS1
ELF2
CTCF
SP4
SIL
ZBTB38
EGR1
C/EBPalpha
SRF
ETS2
EPAS1
ZBTB4
Sin3A
HOXB5
AP-2A
CTIP2
HOXD3
PLAG1
LRRFIP1
HEY1
FOXC2
ELF4
HOXA9
Oct-6
c-Fos
HOXA13
HIF1A

r

n

11
6
5
2
3
2
1
1
3
3
3
2
2
1
1
1
3
1
1
1
1
1
1
1
1
1
2
1
2

R

25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25

N

1283
333
229
4
34
28
1
1
172
185
209
57
58
2
2
2
226
3
3
4
4
5
5
7
7
8
121
9
132

mean

19665
19665
19665
19665
19665
19665
19665
19665
19665
19665
19665
19665
19665
19665
19665
19665
19665
19665
19665
19665
19665
19665
19665
19665
19665
19665
19665
19665
19665

z-score

1.63107
0.423341
0.291126
0.005085
0.043224
0.035596
0.001271
0.001271
0.218663
0.235189
0.2657
0.072464
0.073735
0.002543
0.002543
0.002543
0.287312
0.003814
0.003814
0.005085
0.005085
0.006356
0.006356
0.008899
0.008899
0.01017
0.153827
0.011442
0.167811

7.592231
8.649733
8.783852
27.99501
14.24285
10.42565
28.02856
28.02856
5.977771
5.731578
5.336239
7.175259
7.108625
19.79446
19.79446
19.79446
5.093282
16.14192
16.14192
13.96183
13.96183
12.4722
12.4722
10.51449
10.51449
9.823042
4.724569
9.249593
4.490431

p-value

1.66E-07
3.04E-06
9.01E-06
9.3E-06
1.06E-05
0.000575
0.001271
0.001271
0.001313
0.001618
0.00229
0.002373
0.002455
0.002541
0.002541
0.002541
0.002858
0.003809
0.003809
0.005076
0.005076
0.006341
0.006341
0.008867
0.008867
0.010127
0.01027
0.011386
0.012126
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:#-/'0%.#%1'%,.)-.%2#+".,%3+",+0'%*-''"%/+-/4',5;%<,+"*%,&#-.',.%2).&$)=%)4*#-+.&(>%
(+789%4+,.%-',.-+/.'0%.#%?@%.&-',&#406%:#-%,+(24+/+.=%

AB%

!"#"$%"&'(&)$"#*'+%&,-,./%*%0&12'$3"%3&),32&($'4&2"4,-5*'4,&
$".,3"6&)$'3"*-%&3'&4*!78&)$'3"*-%&9:;<=&32$"%2'.6>&

??&

!"#$%#$#&'%()$*&+,,-.*"(/&0-&1"-2%.)$.#&
3-(45&2"'6+&4"#07&
Disease

ratio

p-value

Uterine Neoplasms

13

541

9.73E-07

Uterine Diseases

13

545

1.06E-06

Leukemia, B-Cell, Chronic

3

24

2.04E-04

Neoplasms by Site

30

3865

4.45E-04

Genital Neoplasms, Female

13

981

5.43E-04

Head and Neck Neoplasms

10

618

6.07E-04

Neuroblastoma

8

404

6.35E-04

Neuroectodermal Tumors,
Primitive, Peripheral
Thyroid Neoplasms

8

415

7.58E-04

6

245

1.11E-03

Adnexal Diseases

13

1072

1.27E-03

Neuroectodermal Tumors,
Primitive
Neoplasms, Neuroepithelial

8

486

2.10E-03

12

992

2.11E-03

Leukemia, B-Cell

3

65

3.82E-03

Papillary Thyroid Carcinoma

3

69

4.53E-03

Eczema

2

24

5.99E-03

'%8-&.$9.$#$(0#&(:2;$.&-<&;"-2%.)$.#&
<-:(*&"(&#%294$&,-29%.$*&0-&)(-=(&
;"-2%.)$.#&,-(0%"($*&"(&0>$&*%0%;%#$&<-.&0>$&
/"?$(&*"#$%#$&

B>$&9C?%4:$&/"?$(&"#&<-.&9",)"(/&%&.%(*-2&
($0=-.)&-<&0>$&#%2$&#"D$&<.-2&0>$&*%0%;%#$&
>%?"(/&0>$&#%2$&-.&/.$%0$.&(:2;$.&-<&
/$($#&<.-2&0>$&0%./$0&4"#0E&

@A&

!"#$%#$#&'%()$*&+,,-.*"(/&0-&1"-2%.)$.#&
32"'4+&5"#0&6&7$2%(/"-2%&'$5%0$*&8.-0$"(#9&
Disease

ratio

p-value

Hemangioma

14

30

2.17E-23

Hemangioma, Capillary

9

9

2.44E-20

Hemangioblastoma

8

8

3.95E-18

Uterine Diseases

24

545

6.85E-14

Neoplasms, Vascular Tissue

14

183

2.20E-11

Uterine Neoplasms

21

541

4.53E-11

Genital Neoplasms, Female

26

981

5.15E-10

Adnexal Diseases

26

1072

3.57E-09

Endocrine Gland Neoplasms

27

1245

1.78E-08

Head and Neck Neoplasms

19

618

2.38E-08

Neoplasms by Site

48

3865

6.61E-08

Thyroid Neoplasms

12

245

1.09E-07

Digestive System Neoplasms

33

1996

1.59E-07

Thyroid Diseases

14

372

2.19E-07

Nervous System Neoplasms

13

326

3.30E-07
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